血清阳性率估计对严重急性呼吸综合征冠状病毒 2 有偏差吗？
Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?
机构信息
EPPIcenter Program, Division of HIV, ID, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Chan Zuckerberg Biohub, San Francisco, California, USA.
出版信息
J Infect Dis. 2020 Nov 9;222(11):1772-1775. doi: 10.1093/infdis/jiaa523.
Abstract
Biased seroprevalence estimates can occur using serological assays optimized with validation sets unrepresentative of disease spectrum in the general population. Correct interpretation of serosurveys for severe acute respiratory syndrome coronavirus 2 requires quantifying variations in sensitivity with disease severity and over time.
摘要
使用优化后的血清学检测方法进行血清学检测时，如果验证集不代表一般人群中的疾病谱，可能会导致偏倚的血清流行率估计。正确解释严重急性呼吸综合征冠状病毒 2 的血清学调查结果需要定量评估灵敏度随疾病严重程度和时间的变化。
相似文献
1
Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?血清阳性率估计对严重急性呼吸综合征冠状病毒 2 有偏差吗？
J Infect Dis. 2020 Nov 9;222(11):1772-1775. doi: 10.1093/infdis/jiaa523.
2
Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.2020 年 4 月伊朗吉兰省 SARS-CoV-2 的血清流行率。
Emerg Infect Dis. 2021 Feb;27(2):636-638. doi: 10.3201/eid2702.201960. Epub 2020 Dec 21.
3
Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.2020 年 6 月日本 SARS-CoV-2 特异性抗体流行情况。
Emerg Infect Dis. 2021 Feb;27(2):628-631. doi: 10.3201/eid2702.204088.
4
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.SARS-CoV-2 感染和 COVID-19 康复过程中抗 SARS-CoV-2 抗体的动态变化。
Nat Commun. 2020 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y.
5
Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure.不同程度接触 2019 年冠状病毒病（COVID-19）患者的医护人员中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）抗体的血清阳性率。
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1441-1442. doi: 10.1017/ice.2020.390. Epub 2020 Aug 3.
6
Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.接受生物治疗的炎症性肠病患者中的无症状严重急性呼吸综合征冠状病毒2感染
Gastroenterology. 2020 Dec;159(6):2229-2231.e2. doi: 10.1053/j.gastro.2020.08.046. Epub 2020 Aug 26.
7
The Potential Transmission of SARS-CoV-2 from Patients with Negative RT-PCR Swab Tests to Others: Two Related Clusters of COVID-19 Outbreak.从 RT-PCR 咽拭子检测阴性的患者向他人传播 SARS-CoV-2 的可能性：两起新冠肺炎暴发的聚集性疫情。
Jpn J Infect Dis. 2020 Nov 24;73(6):399-403. doi: 10.7883/yoken.JJID.2020.165. Epub 2020 May 29.
8
SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.2020 年 8 月至 9 月印度 SARS-CoV-2 抗体血清阳性率：第二次全国家庭血清学调查结果。
Lancet Glob Health. 2021 Mar;9(3):e257-e266. doi: 10.1016/S2214-109X(20)30544-1. Epub 2021 Jan 27.
9
Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing.远程末梢血采集用于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）抗体检测。
Arch Pathol Lab Med. 2021 Apr 1;145(4):415-418. doi: 10.5858/arpa.2020-0713-SA.
10
SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.加拿大第一波 COVID-19 疫情后献血者中的 SARS-CoV-2 血清流行率。
Transfusion. 2021 Mar;61(3):862-872. doi: 10.1111/trf.16296. Epub 2021 Feb 23.
引用本文的文献
1
Potential for Bias in Prevalence Estimates when Not Accounting for Test Sensitivity and Specificity: A Systematic Review of COVID-19 Seroprevalence Studies.在不考虑检测敏感性和特异性时患病率估计中的偏倚可能性：COVID-19血清流行率研究的系统评价
Int J Public Health. 2025 Jul 15;70:1608343. doi: 10.3389/ijph.2025.1608343. eCollection 2025.
2
Interpreting the Influence of Using Blood Donor Residual Samples for SARS-CoV-2 Seroprevalence Studies in Japan: Cross-Sectional Survey Study.解读日本使用献血者剩余样本进行SARS-CoV-2血清流行率研究的影响：横断面调查研究
JMIR Public Health Surveill. 2025 Feb 10;11:e60467. doi: 10.2196/60467.
3
Inferring the proportion of undetected cholera infections from serological and clinical surveillance in an immunologically naive population.通过对免疫未接触人群的血清学和临床监测推断未检测到的霍乱感染比例。
Epidemiol Infect. 2024 Dec 2;152:e149. doi: 10.1017/S0950268824000888.
4
Who is missed in a community-based survey: Assessment and implications of biases due to incomplete sampling frame in a community-based serosurvey, Choma and Ndola Districts, Zambia, 2022.在基于社区的调查中被遗漏的人群：2022年赞比亚乔马和恩多拉地区基于社区的血清学调查中由于抽样框架不完整导致的偏差评估及其影响
PLOS Glob Public Health. 2024 Apr 29;4(4):e0003072. doi: 10.1371/journal.pgph.0003072. eCollection 2024.
5
Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model.利用血清学数据和贝叶斯混合模型估计新冠病毒感染概率。
Sci Rep. 2024 Apr 25;14(1):9503. doi: 10.1038/s41598-024-60060-3.
6
Estimating geographic variation of infection fatality ratios during epidemics.估算疫情期间感染致死率的地理差异。
Infect Dis Model. 2024 Mar 4;9(2):634-643. doi: 10.1016/j.idm.2024.02.009. eCollection 2024 Jun.
7
Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study.2021年2月至2022年4月期间马拉维城乡地区新冠病毒血清流行率变化特征：一项基于人群的队列研究
Int J Infect Dis. 2023 Dec;137:118-125. doi: 10.1016/j.ijid.2023.10.020. Epub 2023 Oct 28.
8
Early detection of new pandemic waves. Control chart and a new surveillance index.新疫情波的早期检测。控制图和新监测指标。
PLoS One. 2024 Feb 12;19(2):e0295242. doi: 10.1371/journal.pone.0295242. eCollection 2024.
9
Estimating cutoff values for diagnostic tests to achieve target specificity using extreme value theory.应用极值理论估计诊断试验的截断值以达到目标特异性。
BMC Med Res Methodol. 2024 Feb 8;24(1):30. doi: 10.1186/s12874-023-02139-5.
10
Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits.2020 年至 2022 年日本医护人员中两种商业试剂盒检测到的 SARS-CoV-2 抗体血清阳性率。
Sci Rep. 2024 Feb 7;14(1):3102. doi: 10.1038/s41598-024-53656-2.
Zotero 插件